Uniqure (NASDAQ:QURE) received a $48.00 target price from research analysts at HC Wainwright in a research note issued on Friday, October 19th. The firm currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target points to a potential upside of 86.63% from the stock’s previous close.
QURE has been the subject of several other research reports. Zacks Investment Research downgraded shares of Uniqure from a “buy” rating to a “hold” rating in a research report on Wednesday, October 17th. BidaskClub downgraded shares of Uniqure from a “buy” rating to a “hold” rating in a research report on Tuesday, October 9th. Cantor Fitzgerald assumed coverage on shares of Uniqure in a research report on Thursday, July 26th. They issued an “overweight” rating and a $58.00 price target for the company. Chardan Capital reissued a “buy” rating and issued a $50.00 price target on shares of Uniqure in a research report on Thursday, October 18th. Finally, Janney Montgomery Scott reissued a “buy” rating on shares of Uniqure in a research report on Wednesday, August 8th. Three investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $49.67.
NASDAQ QURE traded down $1.51 during trading hours on Friday, reaching $25.72. The company’s stock had a trading volume of 242,562 shares, compared to its average volume of 293,676. The company has a current ratio of 7.56, a quick ratio of 8.36 and a debt-to-equity ratio of 0.05. Uniqure has a 52 week low of $13.71 and a 52 week high of $43.23.
Hedge funds have recently bought and sold shares of the business. OppenheimerFunds Inc. purchased a new position in Uniqure during the 2nd quarter valued at about $63,553,000. Swiss National Bank purchased a new position in shares of Uniqure during the second quarter worth about $1,550,000. BlackRock Inc. grew its holdings in shares of Uniqure by 6.7% during the second quarter. BlackRock Inc. now owns 464,426 shares of the biotechnology company’s stock worth $17,555,000 after purchasing an additional 29,299 shares in the last quarter. Macquarie Group Ltd. grew its holdings in shares of Uniqure by 1.5% during the second quarter. Macquarie Group Ltd. now owns 598,900 shares of the biotechnology company’s stock worth $22,639,000 after purchasing an additional 8,900 shares in the last quarter. Finally, Baker BROS. Advisors LP grew its holdings in shares of Uniqure by 21.0% during the second quarter. Baker BROS. Advisors LP now owns 605,000 shares of the biotechnology company’s stock worth $22,869,000 after purchasing an additional 105,000 shares in the last quarter. 59.10% of the stock is owned by institutional investors and hedge funds.
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease.
Featured Article: What Factors Can Affect Return on Equity?
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.